A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis

Objectives: To compare the safety and efficacy of thalidomide in combination with carboplatin to carboplatin alone as a first-line therapy in women with ovarian cancer and to evaluate the anti-angiogenic effects of thalidomide by measurement of surrogate markers of angiogenesis. Methods: Forty patients with Stage IC-IV ovarian cancer were randomly assigned to receive either carboplatin (AUC 7) intravenously every four weeks for up to six doses (n = 20) or carboplatin at the same dose and schedule, plus thalidomide 100 mg orally daily for six months (n = 20). Results: After median follow-up of 1.95 years, there was no difference in the overall response rate (90% in carboplatin arm, 75% in combination arm; p = 0.41). Increased incidence of symptoms of constipation, dizziness, tiredness and peripheral neuropathy was observed in the combination arm. There was a significant fall in CA-125 and E-selectin in both arms after treatment and VCAM-1 in the carboplatin arm. No significant difference between the two arms was observed in any of the markers analysed. Conclusions: In our trial the addition of thalidomide to carboplatin was well tolerated with no increased efficacy. The fall in some of the angiogenic markers in both groups may reflect tumour response rather than any specific anti-angiogenic effect of thalidomide.

Angiogenesis; Carboplatin; Ovarian cancer; Phase II trial; Thalidomide

[1] Neijt J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C. et al.: “Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer”. J. Clin. Oncol., 2000, 18, 3084.

[2] Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R. et al.: “Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma”. J. Natl. Cancer Inst., 2004, 96, 1682.

[3] ICON collaborators: “Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial”. Lancet, 2002, 360, 505.

[4] Reynolds K., Farzaneh F., Collins W.P., Campbell S., Bourne T.H., Lawton F. et al.: “Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor”. J. Natl. Cancer Inst., 1994, 86, 1234.

[5] Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K. et al.: “Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels”. Br. J. Cancer, 1997, 76, 1221.

[6] Mesiano S., Ferrara N., Jaffe R.B.: “Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization”. Am. J. Pathol., 1998, 153, 1249.

[7] Chen C.A., Cheng W.F., Lee C.N., Chen T.M., Kung C.C., Hsieh F.J., Hsieh C.Y.: “Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival”. Gynecol. Oncol., 1999, 74, 235.

[8]

Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., Kainz C.: “Vascular endothelial growth factor serum concentrations in ovarian cancer”. Obstet. Gynecol., 1998, 92, 360.

[9] Dirix L.Y., Vermeulen P.B., Pawinski A., Prové A., Benoy I., De Pooter C. et al.: “Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients”. Br. J. Cancer, 1997, 76, 238.

[10] Banks R.E., Gearing A.J., Hemingway I.K., Norfolk D.R., Perren T.J., Selby P.J.: “Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies”. Br. J. Cancer, 1993, 68, 122.

[11] Gadducci A., Baicchi U., Marrai R., Del Bravo B., Fosella P.V., Facchini V.: “Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma”. Gynecol. Oncol., 1994, 53, 352.

[12] Qiao X.M., Wang Z.M.: “Significance of concentration of serum soluble vascular cell adhesion molecule-1 in epithelial ovarian carcinoma”. Ai Zheng, 2004, 23, 81.

[13] D’Amato R.J., Loughnan M.S., Flynn E., Folkman J.: “Thalidomide is an inhibitor of angiogenesis”. Proc. Natl. Acad. Sci USA, 1994, 91, 4082.

[14] Moreira A.L., Sampaio E.P., Zmuidzinas A., Frindt P., Smith K.A., Kaplan G.: “Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation”. J. Exp. Med., 1993, 177, 1675.

[15] McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M., Ewan P.W.: “The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures”. Clin. Exp. Immunol., 1995, 99, 160.

[16] Kumar S., Witzig T.E., Rajkumar S.V.: “Thalidomide: current role in the treatment of non-plasma cell malignancies”. J. Clin. Oncol., 2004, 22, 2477.

[17] Chan J.K., Manuel M.R., Ciaravino G., Cheung M.K., Husain A., Teng N.N.: “Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma”. Gynecol. Oncol., 2006, 103, 919.

[18] Gordinier M.E., Dizon D.S., Weitzen S., Disilvestro P.A., Moore R.G., Granai C.O.: “Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer”. J. Palliat. Med., 2007, 10, 61.

[19] Chintagumpala M., Blaney S.M., Bomgaars L.R., Aleksic A., Kuttesch J.F., Klenke R.A., Berg S.L.: “Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer”. J. Clin. Oncol., 2004, 22, 4394.

[20] Merchant J.J., Kim K., Mehta M.P., Ripple G.H., Larson M.L., Brophy D.J. et al.: “Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer”. Clin. Lung Cancer, 2000, 2, 48.

[21] Bastuji-Garin S., Ochonisky S., Bouche P., Gherardi R.K., Duguet C., Djerradine Z. et al.: “Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients”. J. Invest. Dermatol., 2002, 119, 1020.

[22] Fullerton P.M., O’Sullivan D.J.: “Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study”. J. Neurol. Neurosurg. Psych., 1968, 31, 543.

[23] Wulff C.H., Hoyer H., Asboe-Hansen G., Brodthagen H.: “Development of polyneuropathy during thalidomide therapy”. Br. J. Dermatol., 1985, 112, 475.

[24] Jodrell D.I., Egorin M.J., Canetta R.M., Langenberg P., Goldbloom E.P., Burroughs J.N. et al.: “Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer”. J. Clin. Oncol., 1992, 10, 520.

[25] Braybrooke J.P., O’Byrne K.J., Propper D.J., Blann A., Saunders M., Dobbs N. et al.: “A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis”. Clin. Cancer Res., 2000, 6, 4697.

[26] Jones P.H., Christodoulos K., Dobbs N., Thavasu P., Balkwill F., Blann A.D. et al.: “Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer”. Br. J. Cancer, 2004, 91, 30.

[27] Deplanque G., Madhusudan S., Jones P.H., Wellmann S., Christodoulos K., Talbot D.C. et al.: “Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma”. Br. J. Cancer, 2004, 91, 1645.

[28] Figg W.D., Dahut W., Duray P., Hamilton M., Tompkins A., Steinberg S.M. et al.: “A randomized phase II trial of thalidomide,an angiogenesis inhibitor, in patients with androgen-independent prostate cancer”. Clin. Cancer Res., 2001, 7, 1888.

[29] Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pryle L. et al.: “Continuous low dose Thalidomide: a phase II study inadvanced melanoma, renal cell, ovarian and breast cancer”. Br. J. Cancer, 2000, 82, 812.

[30] Downs L.S. Jr., Judson P.L., Argenta P.A., Ghebre R., Geller M.A., Bliss R.L. et al.: “A prospective randomized trial of thalidomide with topotecan compared with topetecan alone in women with recurrent epithelial ovarian carcinoma”. Cancer, 2008, 112, 331.

[31] Dahut W.L., Gulley J.L., Arlen P.M., Liu Y., Fedenko K.M., Steinberg S.M. et al.: “Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer”. J. Clin. Oncol., 2004, 22, 2532.

[32] Steins M.B., Padro T., Bieker R., Ruiz S., Kropff M., Kienast J. et al.: “Efficacy and safety of thalidomide in patients with acute myeloid leukemia”. Blood, 2002, 99, 834.

[33] Piccaluga P.P., Visani G., Pileri S.A., Ascani S., Grafone T., Isidori A. et al.: “Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study”. Leukemia, 2002, 16, 1609.

[34] Shaked Y., Bertolini F., Man S., Rogers M.S., Cervi D., Foutz T. et al.: “Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis”. Cancer Cell., 2005, 7, 101.

[35] Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T. et al.: “Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer”. Nat. Med., 2004, 10, 145.

[36] Schneider M., Tjwa M., Carmeliet P.: “A surrogate marker to monitor angiogenesis at last”. Cancer Cell., 2005, 7, 3.

[37] Hurteaua J.A., Brady M.F., Darcy K.M., McGuire W.F., Edmonds P., Pearle L.M. et al..: “Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical recurrent only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after complete response to first line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynaecological Oncology Group Study”. Gynaecol. Oncol., 2010, 119, 444.